"There's a lot to like about how our teams are delivering for customers, particularly amidst an uncertain economy," said CEO Andy Jassy. Read More...
Benzinga
Why AbbVie Shares Are Trading Lower Today
AbbVie Inc (NYSE: ABBV) has reported Q1 adjusted EPS of $2.46, down 22.2% Y/Y, in line with the consensus. Overall sales decreased 9.7% Y/Y (down 8.3% on an operational basis) to $12.23 billion, beating the consensus of $12.17 billion. The immunology portfolio generated $5.59 billion in sales, down 9% (-7.8% on an operational basis). Humira sales decreased 25.2% to $3.54 billion. In Q4, Humira sales increased 4.6% to $5.56 billion. Skyrizi sales reached $1.36 billion (+44.7% Y/Y), and Rinvoq jum
Add Comment